Surgical Management of Small Bowel Lymphoma

Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcome...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastrointestinal surgery 2021-03, Vol.25 (3), p.757-765
Main Authors: Lu, Pamela W., Fields, Adam C., Yoo, James, Irani, Jennifer, Goldberg, Joel E., Bleday, Ronald, Melnitchouk, Nelya
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Disease
Duodenal Neoplasms
Gastroenterology
Histology
Hospitals
Humans
Intestine, Small - surgery
Lymphoma
Lymphoma - surgery
Medical diagnosis
Medicine
Medicine & Public Health
Neoplasm Staging
Original Article
Patients
Proportional Hazards Models
Rare diseases
Retrospective Studies
Small intestine
Statistical analysis
Surgery
Surgical outcomes
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcomes in patients with small bowel lymphoma. Materials and Methods Patients diagnosed with stage I–III small bowel lymphoma in 2004–2015 who underwent surgery were identified in the National Cancer Database. Two cohorts were created based on systemic chemotherapy treatment status. The primary outcome was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival. Results 2283 patients met inclusion criteria Of these patients, 826 patients (36%) underwent surgical resection alone, and 1457 patients (64%) underwent resection with systemic chemotherapy. Chemotherapy was associated with improved overall survival in unadjusted (5-year overall survival, 55% versus 70%) and adjusted analysis (HR 0.54, 95% CI 0.47–0.63, p  
ISSN:1091-255X
1873-4626
DOI:10.1007/s11605-020-04730-3